Physician profile
Karan Raghavan
NPI 1518596683
$984.19
in general payments reported to CMS, 2019-2025
14 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.70 · 2021: $14.65 · 2022: $156 · 2023: $203 · 2024: $286 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $347.84 | 2023-2025 | Farxiga, Airsupra, Breztri |
| E.R. Squibb & Sons, L.L.C. | $139.64 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $94.07 | 2024-2025 | Nuzyra, Xhance |
| Novo Nordisk INC | $73.00 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $71.48 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $48.09 | 2024 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $44.54 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.06 | 2024-2025 | Jardiance |
| Pfizer INC. | $38.62 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.27 | 2022 | |
| Cardiovascular Systems INC. | $19.71 | 2023 | |
| Currax Pharmaceuticals LLC | $15.98 | 2025 | Contrave |
| Exact Sciences Corporation | $15.89 | 2023 | Cologuard Collection Kit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Raghavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.